GlassScriptPhysician profile
Danielle Therese Callegari
NPI 1013269661
$5,421.23
in general payments reported to CMS, 2019-2025
26 companies · $896 in 2025
The $896 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $307 · 2021: $937 · 2022: $1,104 · 2023: $793 · 2024: $666 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,314.93 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Bausch & Lomb Americas INC. | $658.73 | 2022-2025 | Infuse, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $452.12 | 2020-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $358.13 | 2022-2025 | Acuvue |
| Aerie Pharmaceuticals, INC. | $257.78 | 2019-2021 | |
| Amgen INC. | $223.45 | 2024-2025 | Tepezza |
| Coopervision INC. | $203.54 | 2019-2022 | |
| Abbvie INC. | $189.17 | 2022-2025 | Lumigan |
| Kala Pharmaceuticals, INC. | $176.58 | 2021-2022 | |
| Dompe US, INC. | $176.48 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $168.94 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $165.42 | 2021-2024 | Tecnis Simplicity |
| Shire North American Group INC | $142.24 | 2019 | |
| Allergan, INC. | $141.99 | 2021-2022 | |
| Glaukos Corporation | $129.36 | 2022-2025 | Idosetr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $122.40 | 2023 | Syfovre |
| Alcon Research LLC | $121.02 | 2019 | |
| Eyepoint US, INC. | $100.00 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $82.77 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $66.13 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.91 | 2019-2020 | |
| Rxsight INC | $32.55 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Biotissue Holdings INC. | $26.36 | 2021 | |
| Harrow Eye, LLC | $25.37 | 2025 | Vevye |
| Sight Sciences, INC. | $19.78 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Callegari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.